The Spectrum of Early Movement Disorders in Congenital Defects of Biogenic Amine Metabolism

 

 Buy Article Permissions and Reprints

Abstract

This article analyzes the pattern of movement disorders in children with primary defects of biogenic amine metabolism emerging during the first 3 year of life. A PubMed search was performed using the keywords “monoamine neurotransmitter disorders,” “congenital defects of biogenic amine metabolism,” “early onset movement disorders,” “autosomal dominant guanosine-triphosphate-cyclohydrolase deficiency,” “autosomal recessive guanosine-tryphosphate-cyclohydrolase deficiency,” “6-pyruvoyl-tethrahydropterin synthase deficiency,” “sepiapterin reductase deficiency,” “dihydropteridine reductase deficiency,” “tyrosine hydroxilase deficiency,” “aromatic l-amino acid decarboxylase deficiency,” “dopamine transporter deficiency,” and “vesicular monoamine transporter 2.” A personal series of 27 patients affected by these disorders was presented and discussed. Primary defects of biogenic amine metabolism result in a spectrum of movement disorders associated with derangement of postural reaction and global development delay. Movement disorders virtually represent the presentation symptoms in most of these diseases. The prominent early clinical patterns of movement disorders are akinesia (with rigidity or hypotonia) and hyperkinesia (dystonia, myoclonic jerks, and tremor). While some diseases present with a rather stereotyped clinical pattern (i.e., Aromatic l-amino acid decarboxylase, sepiapterin reductase, and Dopamine transporter deficiencies), others (i.e., Guanosine-triphosphate-cyclohydrolase, 6-pyruvoyl tetrahydropterin synthase, dihydropteridine reductase, and tyrosine hydroxylase deficiencies) may present with more pleomorphic features. As a general rule, earlier the onset of the disease is, more severe and generalized is the derangement of motor functions. Inherited disorders of monoamine neurotransmitter metabolism include the few idiopathic movement disorders with the possibility of etiological treatments. For these reasons, they should always be considered in the diagnostic work-up of children with early onset movement disorders.

• References

• 1 Kurian MA, Gissen P, Smith M, Heales Jr S, Clayton PT. The monoamine neurotransmitter disorders: an expanding range of neurological syndromes. Lancet Neurol 2011; 10 (8) 721-733
  CrossrefPubMedGoogle Scholar
• 2 Pearl PL, Taylor JL, Trzcinski S, Sokohl A. The pediatric neurotransmitter disorders. J Child Neurol 2007; 22 (5) 606-616
  CrossrefPubMedGoogle Scholar
• 3 Donaldson IM, Marsden CD, Schneider SA, Bathia KP. Marsden's Book of Movement Disorders. Oxford, UK: Oxford University Press; 2012: 139-143
  Google Scholar
• 4 Kaufman S, Holtzman NA, Milstien S, Butler LJ, Krumholz A. Phenylketonuria due to a deficiency of dihydropteridine reductase. N Engl J Med 1975; 293 (16) 785-790
  CrossrefPubMedGoogle Scholar
• 5 Niederwieser A, Curtius HC, Bettoni O , et al. Atypical phenylketonuria caused by 7, 8-dihydrobiopterin synthetase deficiency. Lancet 1979; 1 (8108) 131-133
  PubMedGoogle Scholar
• 6 Stamelou M, Hoeglinger GU. Atypical parkinsonism: an update. Curr Opin Neurol 2013; 26 (4) 401-405
  CrossrefPubMedGoogle Scholar
• 7 Sanger TD, Chen D, Fehlings DL , et al. Definition and classification of hyperkinetic movements in childhood. Mov Disord 2010; 25 (11) 1538-1549
  CrossrefPubMedGoogle Scholar
• 8 Hagenah J, Saunders-Pullman R, Hedrich K , et al. High mutation rate in dopa-responsive dystonia: detection with comprehensive GCHI screening. Neurology 2005; 64 (5) 908-911
  CrossrefPubMedGoogle Scholar
• 9 Segawa M. Autosomal dominant GTP cyclohydrolase I (AD GCH 1) deficiency (Segawa disease, dystonia 5; DYT 5). Chang Gung Med J 2009; 32 (1) 1-11
  PubMedGoogle Scholar
• 10 Trender-Gerhard I, Sweeney MG, Schwingenschuh P , et al. Autosomal-dominant GTPCH1-deficient DRD: clinical characteristics and long-term outcome of 34 patients. J Neurol Neurosurg Psychiatry 2009; 80 (8) 839-845
  CrossrefPubMedGoogle Scholar
• 11 Clot F, Grabli D, Cazeneuve C , et al; French Dystonia Network Exhaustive analysis of BH4 and dopamine biosynthesis genes in patients with Dopa-responsive dystonia. Brain 2009; 132 (Pt 7) 1753-1763
  CrossrefPubMedGoogle Scholar
• 12 Bandmann O, Wood NW. Dopa-responsive dystonia — the story so far. Neuropediatrics 2002; 33 (1) 1-5
  Article in Thieme ConnectPubMedGoogle Scholar
• 13 Nygaard TG, Waran SP, Levine RA, Naini AB, Chutorian AM. Dopa-responsive dystonia simulating cerebral palsy. Pediatr Neurol 1994; 11 (3) 236-240
  CrossrefPubMedGoogle Scholar
• 14 López-Laso E, Ochoa-Sepúlveda JJ, Ochoa-Amor JJ , et al. Segawa syndrome due to mutation Q89X in the GCH1 gene: a possible founder effect in Córdoba (southern Spain). J Neurol 2009; 256 (11) 1816-1824
  CrossrefPubMedGoogle Scholar
• 15 Jan MM. Misdiagnoses in children with dopa-responsive dystonia. Pediatr Neurol 2004; 31 (4) 298-303
  CrossrefPubMedGoogle Scholar
• 16 Wider C, Skipper L, Solida A , et al. Autosomal dominant dopa-responsive parkinsonism in a multigenerational Swiss family. Parkinsonism Relat Disord 2008; 14 (6) 465-470
  CrossrefPubMedGoogle Scholar
• 17 Furukawa Y, Guttman M, Sparagana SP , et al. Dopa-responsive dystonia due to a large deletion in the GTP cyclohydrolase I gene. Ann Neurol 2000; 47 (4) 517-520
  CrossrefPubMedGoogle Scholar
• 18 Leuzzi V, Carducci C, Carducci C, Cardona F, Artiola C, Antonozzi I. Autosomal dominant GTP-CH deficiency presenting as a dopa-responsive myoclonus-dystonia syndrome. Neurology 2002; 59 (8) 1241-1243
  CrossrefPubMedGoogle Scholar
• 19 Opladen T, Hoffmann GF, Blau N. An international survey of patients with tetrahydrobiopterin deficiencies presenting with hyperphenylalaninaemia. J Inherit Metab Dis 2012; 35 (6) 963-973
  CrossrefPubMedGoogle Scholar
• 20 Horvath GA, Stockler-Ipsiroglu SG, Salvarinova-Zivkovic R , et al. Autosomal recessive GTP cyclohydrolase I deficiency without hyperphenylalaninemia: evidence of a phenotypic continuum between dominant and recessive forms. Mol Genet Metab 2008; 94 (1) 127-131
  CrossrefPubMedGoogle Scholar
• 21 Opladen T, Hoffmann G, Hörster F , et al. Clinical and biochemical characterization of patients with early infantile onset of autosomal recessive GTP cyclohydrolase I deficiency without hyperphenylalaninemia. Mov Disord 2011; 26 (1) 157-161
  CrossrefPubMedGoogle Scholar
• 22 Bodzioch M, Lapicka-Bodzioch K, Rudzinska M, Pietrzyk JJ, Bik-Multanowski M, Szczudlik A. Severe dystonic encephalopathy without hyperphenylalaninemia associated with an 18-bp deletion within the proximal GCH1 promoter. Mov Disord 2011; 26 (2) 337-340
  CrossrefPubMedGoogle Scholar
• 23 Brüggemann N, Spiegler J, Hellenbroich Y , et al. Beneficial prenatal levodopa therapy in autosomal recessive guanosine triphosphate cyclohydrolase 1 deficiency. Arch Neurol 2012; 69 (8) 1071-1075
  CrossrefPubMedGoogle Scholar
• 24 Nardocci N, Zorzi G, Blau N , et al. Neonatal dopa-responsive extrapyramidal syndrome in twins with recessive GTPCH deficiency. Neurology 2003; 60 (2) 335-337
  CrossrefPubMedGoogle Scholar
• 25 Furukawa Y, Kish SJ, Bebin EM , et al. Dystonia with motor delay in compound heterozygotes for GTP-cyclohydrolase I gene mutations. Ann Neurol 1998; 44 (1) 10-16
  CrossrefPubMedGoogle Scholar
• 26 Hwu WL, Wang PJ, Hsiao KJ, Wang TR, Chiou YW, Lee YM. Dopa-responsive dystonia induced by a recessive GTP cyclohydrolase I mutation. Hum Genet 1999; 105 (3) 226-230
  CrossrefPubMedGoogle Scholar
• 27 Dhondt JL, Guibaud P, Rolland MO , et al. Neonatal hyperphenylalaninaemia presumably caused by a new variant of biopterin synthetase deficiency. Eur J Pediatr 1988; 147 (2) 153-157
  CrossrefPubMedGoogle Scholar
• 28 Jäggi L, Zurflüh MR, Schuler A , et al. Outcome and long-term follow-up of 36 patients with tetrahydrobiopterin deficiency. Mol Genet Metab 2008; 93 (3) 295-305
  CrossrefPubMedGoogle Scholar
• 29 Blau N, Barnes I, Dhondt JL. International database of tetrahydrobiopterin deficiencies. J Inherit Metab Dis 1996; 19 (1) 8-14
  PubMedGoogle Scholar
• 30 Dudesek A, Röschinger W, Muntau AC , et al. Molecular analysis and long-term follow-up of patients with different forms of 6-pyruvoyl-tetrahydropterin synthase deficiency. Eur J Pediatr 2001; 160 (5) 267-276
  CrossrefPubMedGoogle Scholar
• 31 Wang L, Yu WM, He C , et al. Long-term outcome and neuroradiological findings of 31 patients with 6-pyruvoyltetrahydropterin synthase deficiency. J Inherit Metab Dis 2006; 29 (1) 127-134
  CrossrefPubMedGoogle Scholar
• 32 Roze E, Vidailhet M, Blau N , et al. Long-term follow-up and adult outcome of 6-pyruvoyl-tetrahydropterin synthase deficiency. Mov Disord 2006; 21 (2) 263-266
  CrossrefPubMedGoogle Scholar
• 33 Bonafé L, Thöny B, Penzien JM, Czarnecki B, Blau N. Mutations in the sepiapterin reductase gene cause a novel tetrahydrobiopterin-dependent monoamine-neurotransmitter deficiency without hyperphenylalaninemia. Am J Hum Genet 2001; 69 (2) 269-277
  CrossrefPubMedGoogle Scholar
• 34 Friedman J, Roze E, Abdenur JE , et al. Sepiapterin reductase deficiency: a treatable mimic of cerebral palsy. Ann Neurol 2012; 71 (4) 520-530
  CrossrefPubMedGoogle Scholar
• 35 Dill P, Wagner M, Somerville A, Thöny B, Blau N, Weber P. Child neurology: paroxysmal stiffening, upward gaze, and hypotonia: hallmarks of sepiapterin reductase deficiency. Neurology 2012; 78 (5) e29-e32
  CrossrefPubMedGoogle Scholar
• 36 Leuzzi V, Carducci C, Tolve M, Giannini MT, Angeloni A, Carducci C. Very early pattern of movement disorders in sepiapterin reductase deficiency. Neurology 2013; 81 (24) 2141-2142
  CrossrefPubMedGoogle Scholar
• 37 Woody RC, Brewster MA, Glasier C. Progressive intracranial calcification in dihydropteridine reductase deficiency prior to folinic acid therapy. Neurology 1989; 39 (5) 673-675
  CrossrefPubMedGoogle Scholar
• 38 Danks DM, Schlesinger P, Firgaira F , et al. Malignant hyperphenylalaninemia—clinical features, biochemical findings, and experience with administration of biopterins. Pediatr Res 1979; 13 (10) 1150-1155
  CrossrefPubMedGoogle Scholar
• 39 Furujo M, Kinoshita M, Ichiba Y, Romstad A, Shintaku H, Kubo T. Clinical characteristics of epileptic seizures in a case of dihydropteridine reductase deficiency. Epilepsy Behav Case Rep 2014; 2: 37-39
  PubMedGoogle Scholar
• 40 Cotton RG, Jennings I, Bracco G, Ponzone A, Guardamagna O. Tetrahydrobiopterin non-responsiveness in dihydropteridine reductase deficiency is associated with the presence of mutant protein. J Inherit Metab Dis 1986; 9 (3) 239-243
  CrossrefPubMedGoogle Scholar
• 41 Lüdecke B, Knappskog PM, Clayton PT , et al. Recessively inherited L-DOPA-responsive parkinsonism in infancy caused by a point mutation (L205P) in the tyrosine hydroxylase gene. Hum Mol Genet 1996; 5 (7) 1023-1028
  CrossrefPubMedGoogle Scholar
• 42 Willemsen MA, Verbeek MM, Kamsteeg EJ , et al. Tyrosine hydroxylase deficiency: a treatable disorder of brain catecholamine biosynthesis. Brain 2010; 133 (Pt 6) 1810-1822
  CrossrefPubMedGoogle Scholar
• 43 Giovanniello T, Leuzzi V, Carducci C , et al. Tyrosine hydroxylase deficiency presenting with a biphasic clinical course. Neuropediatrics 2007; 38 (4) 213-215
  Article in Thieme ConnectPubMedGoogle Scholar
• 44 Stamelou M, Mencacci NE, Cordivari C , et al. Myoclonus-dystonia syndrome due to tyrosine hydroxylase deficiency. Neurology 2012; 79 (5) 435-441
  CrossrefPubMedGoogle Scholar
• 45 Pons R, Syrengelas D, Youroukos S , et al. Levodopa-induced dyskinesias in tyrosine hydroxylase deficiency. Mov Disord 2013; 28 (8) 1058-1063
  CrossrefPubMedGoogle Scholar
• 46 Dionisi-Vici C, Hoffmann GF, Leuzzi V , et al. Tyrosine hydroxylase deficiency with severe clinical course: clinical and biochemical investigations and optimization of therapy. J Pediatr 2000; 136 (4) 560-562
  CrossrefPubMedGoogle Scholar
• 47 Chi CS, Lee HF, Tsai CR. Tyrosine hydroxylase deficiency in Taiwanese infants. Pediatr Neurol 2012; 46 (2) 77-82
  CrossrefPubMedGoogle Scholar
• 48 Giovanniello T, Claps D, Carducci C , et al. A new tyrosine hydroxylase genotype associated with early-onset severe encephalopathy. J Child Neurol 2012; 27 (4) 523-525
  CrossrefPubMedGoogle Scholar
• 49 Brun L, Ngu LH, Keng WT , et al. Clinical and biochemical features of aromatic L-amino acid decarboxylase deficiency. Neurology 2010; 75 (1) 64-71
  CrossrefPubMedGoogle Scholar
• 50 Pons R, Ford B, Chiriboga CA , et al. Aromatic L-amino acid decarboxylase deficiency: clinical features, treatment, and prognosis. Neurology 2004; 62 (7) 1058-1065
  CrossrefPubMedGoogle Scholar
• 51 Hyland K, Clayton PT. Aromatic amino acid decarboxylase deficiency in twins. J Inherit Metab Dis 1990; 13 (3) 301-304
  CrossrefPubMedGoogle Scholar
• 52 Tay SK, Poh KS, Hyland K , et al. Unusually mild phenotype of AADC deficiency in 2 siblings. Mol Genet Metab 2007; 91 (4) 374-378
  CrossrefPubMedGoogle Scholar
• 53 Mastrangelo M, Caputi C, Galosi S, Giannini MT, Leuzzi V. Transdermal rotigotine in the treatment of aromatic L-amino acid decarboxylase deficiency. Mov Disord 2013; 28 (4) 556-557
  CrossrefPubMedGoogle Scholar
• 54 Leuzzi V, Mastrangelo M, Polizzi A , et al. Report of two never treated adult sisters with aromatic L-amino Acid decarboxylase deficiency: a portrait of the natural history of the disease or an expanding phenotype?. JIMD Rep 2015; 15: 39-45
  PubMedGoogle Scholar
• 55 Fiumara A, Bräutigam C, Hyland K , et al. Aromatic L-amino acid decarboxylase deficiency with hyperdopaminuria. Clinical and laboratory findings in response to different therapies. Neuropediatrics 2002; 33 (4) 203-208
  Article in Thieme ConnectPubMedGoogle Scholar
• 56 Kurian MA, Li Y, Zhen J , et al. Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: an observational cohort and experimental study. Lancet Neurol 2011; 10 (1) 54-62
  CrossrefPubMedGoogle Scholar
• 57 Ng J, Zhen J, Meyer E , et al. Dopamine transporter deficiency syndrome: phenotypic spectrum from infancy to adulthood. Brain 2014; 137 (Pt 4) 1107-1119
  CrossrefPubMedGoogle Scholar
• 58 Assmann BE, Robinson RO, Surtees RA , et al. Infantile Parkinsonism-dystonia and elevated dopamine metabolites in CSF. Neurology 2004; 62 (10) 1872-1874
  CrossrefPubMedGoogle Scholar
• 59 Rilstone JJ, Alkhater RA, Minassian BA. Brain dopamine-serotonin vesicular transport disease and its treatment. N Engl J Med 2013; 368 (6) 543-550
  CrossrefPubMedGoogle Scholar